| yan, xiaolong |
TERMGGO, NCT04982900: Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities |
|
|
| Recruiting | 2 | 138 | RoW | furmonertinib, AST2818, Placebo | Ruijin Hospital, Fujian Medical University Union Hospital, First Affiliated Hospital of Zhejiang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University | Multiple Primary Lung Cancers | 08/22 | 08/22 | | |
NCT05400070: Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC |
|
|
| Active, not recruiting | 2 | 45 | RoW | Neoadjuvant therapy 1, anlotinib 10mg, po, qd1-14, q3w, Chemotherapy, Sintilimab (200mg fixed dose) iv, d1, q3w | Tang-Du Hospital | Sintilimab, Lung Cancer, Anlotinib, Chemotherapy | 12/23 | 12/26 | | |
NO.202405-11, NCT06475755: Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC |
|
|
| Not yet recruiting | 2 | 178 | RoW | Immunochemotherapy combined with antiangiogenic, Tislelizumab, Anlotinib, Cisplatin, Carboplatin, Paclitaxel, Albumin-bound paclitaxel, Pemetrexed, Immunochemotherapy | Tang-Du Hospital | Non-Small Cell Lung Cancer, Anti Angiogenesis | 06/25 | 12/27 | | |
NCT06485544: Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial |
|
|
| Recruiting | 2 | 104 | RoW | Adebrelimab + Etoposide + Platinum-based Therapy, Etoposide + Platinum-based Therapy | Tang-Du Hospital | Small Cell Lung Cancer (SCLC) | 12/25 | 12/26 | | |
NCT06006650: Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell |
|
|
| Recruiting | 2 | 114 | RoW | Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin | Tang-Du Hospital | Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma | 12/31 | 12/31 | | |
NCT06644066: Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane |
|
|
| Recruiting | N/A | 60 | RoW | Partial pressure of Oxygen Control method | Tang-Du Hospital | Lung Cancer | 07/24 | 12/24 | | |
NCT06028412: Comparison of Sublobar and Lobectomy in Small (2 Cm or Less 0.5 |
|
|
| Enrolling by invitation | N/A | 660 | RoW | Sublobar, Lobectomy | Xiaolong Yan, Dr. | NSCLC, Stage I | 12/29 | 12/30 | | |
| Liu, Linna |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
NO.202405-11, NCT06475755: Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC |
|
|
| Not yet recruiting | 2 | 178 | RoW | Immunochemotherapy combined with antiangiogenic, Tislelizumab, Anlotinib, Cisplatin, Carboplatin, Paclitaxel, Albumin-bound paclitaxel, Pemetrexed, Immunochemotherapy | Tang-Du Hospital | Non-Small Cell Lung Cancer, Anti Angiogenesis | 06/25 | 12/27 | | |
NCT06040606: Postoperative Complications and Mortality With In-Hospital COVID-19 Omicron Infection After Surgery |
|
|
| Completed | N/A | 119 | RoW | In-Hospital COVID-19 Omicron Infection after surgery | Tang-Du Hospital | Postoperative Complications, Morality | 03/23 | 03/23 | | |
